Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study

Journal:
Annals of the Rheumatic Diseases
Published:
DOI:
10.1016/j.ard.2026.03.013
Affiliations:
17
Authors:
19
Go to article
Institutions Authors Share
AbbVie, United States of America (USA)
4.058824
 0.21
Rheumatologisch-Immunologische Arztpraxis Templin, Germany
1.058824
 0.06
AbbVie - Spain, Spain
1.058824
 0.06
University of California, Los Angeles (UCLA), United States of America (USA)
1.058824
 0.06
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)
1.058824
 0.06
AbbVie Deutschland GmbH & Co. KG, Germany
1.058824
 0.06
Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Brazil
1.058824
 0.06
Laval University (UL), Canada
1.058824
 0.06
AbbVie Kft. - Hungary, Hungary
1.058824
 0.06
Organización Médica de Investigación (OMI), Argentina
1.058824
 0.06
Peking University First Hospital, PKUHSC, China
1.058824
 0.06
Willow Rheumatology and Wellness, United States of America (USA)
1.058824
 0.06
Keio University, Japan
1.058824
 0.06
University of Crete (UOC), Greece
0.558824
 0.03
Foundation for Research and Technology - Hellas (FORTH), Greece
0.558824
 0.03
Carol Davila University of Medicine and Pharmacy (UMFCD), Romania
0.558824
 0.03
Saint Mary Hospital, Romania
0.558824
 0.03
Interested in Pharmacology and Pharmaceutical Sciences?